Findings from this study by Jia et al. provide intriguing therapeutic potential for altering Nrf2 PPARγ crosstalk in M-MDSCs in kidney diseases.2 The role of Nrf2−/− G-MDSCs and Nrf2−/− M-MDSCs on tumor size and tumor angiogenesis will complicate the potential therapeutic value of Nrf2-deficient M-MDSCs for kidney diseases. Here, PPARG is linked to neoplasm.